The Phase 3 study is a randomized, multicenter study evaluating the efficacy and safety of ARINA-1 in the prevention of BOS progression in individuals with a bilateral lung transplant.
The study is expected to enroll approximately 100 participants across 15 sites in the US.
Bronchiolitis obliterans syndrome is the most common form of chronic lung allograft dysfunction after lung transplantation and is the leading cause of graft failure and mortality in lung transplant with approximately 50% of all lung transplant patients developing BOS within 5 years of transplant.
BOS is a rapidly progressive inflammatory rare disease that irreversibly destroys the airways of the lungs and usually leads to respiratory failure and death within 2 to 4 years after diagnosis.
Currently, there are no FDA-approved therapies to treat pre-BOS or BOS. The off-label therapies used to treat BOS are often toxic with serious side effect risks, including significantly increasing infection risk.
Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases.
ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health.
ARINA-1 is poised to start clinical trials in chronic inflammatory airways diseases, including non-cystic fibrosis bronchiectasis (NCFBE) and non-tuberculous mycobacteria-pulmonary disease (NTM-PD).
The Renovion team has in-depth experience in drug development with extensive scientific expertise in chronic pulmonary conditions and inflammation.
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership
Vicinitas Therapeutics Launches with USD 65m in Series A Financing